Letaplimab

莱特利单抗

Report date: 2026/03/29 20:00:13

Base Information

Drug NameLetaplimab
Drug Alias NameIBI-188
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesAdenocarcinoma of Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesInnovent Biologics(Suzhou) Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesAdenocarcinoma of Lung +[6] 

Other Information

ATC CodeN/A
Related LinksN/A